Here’s a biotech company you don’t hear much about, but whose stock has jumped 325% in the last year - Encysive Pharmaceuticals (ENCY). Nine analysts rate it a buy or outperform, it has a promising pipeline, with a Phase III drug that should go to NDA in Q1 ’05. The stock is around 9.00 with a First Call target of 13.7. Keep an eye on the trials for Sitaxentan (Thelin), and get in before the approval if all looks good.
